Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 181

1.

Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma.

Graham RP, Barr Fritcher EG, Pestova E, Schulz J, Sitailo LA, Vasmatzis G, Murphy SJ, McWilliams RR, Hart SN, Halling KC, Roberts LR, Gores GJ, Couch FJ, Zhang L, Borad MJ, Kipp BR.

Hum Pathol. 2014 Aug;45(8):1630-8. doi: 10.1016/j.humpath.2014.03.014. Epub 2014 Apr 13.

PMID:
24837095
2.

Intraductal papillary neoplasms of the bile duct: stepwise progression to carcinoma involves common molecular pathways.

Schlitter AM, Born D, Bettstetter M, Specht K, Kim-Fuchs C, Riener MO, Jeliazkova P, Sipos B, Siveke JT, Terris B, Zen Y, Schuster T, Höfler H, Perren A, Klöppel G, Esposito I.

Mod Pathol. 2014 Jan;27(1):73-86. doi: 10.1038/modpathol.2013.112. Epub 2013 Jul 5.

3.

Morphological subclassification of intrahepatic cholangiocarcinoma: etiological, clinicopathological, and molecular features.

Liau JY, Tsai JH, Yuan RH, Chang CN, Lee HJ, Jeng YM.

Mod Pathol. 2014 Aug;27(8):1163-73. doi: 10.1038/modpathol.2013.241. Epub 2014 Jan 10.

4.

Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors.

Andersen JB, Spee B, Blechacz BR, Avital I, Komuta M, Barbour A, Conner EA, Gillen MC, Roskams T, Roberts LR, Factor VM, Thorgeirsson SS.

Gastroenterology. 2012 Apr;142(4):1021-1031.e15. doi: 10.1053/j.gastro.2011.12.005. Epub 2011 Dec 13.

5.

Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma.

Borad MJ, Champion MD, Egan JB, Liang WS, Fonseca R, Bryce AH, McCullough AE, Barrett MT, Hunt K, Patel MD, Young SW, Collins JM, Silva AC, Condjella RM, Block M, McWilliams RR, Lazaridis KN, Klee EW, Bible KC, Harris P, Oliver GR, Bhavsar JD, Nair AA, Middha S, Asmann Y, Kocher JP, Schahl K, Kipp BR, Barr Fritcher EG, Baker A, Aldrich J, Kurdoglu A, Izatt T, Christoforides A, Cherni I, Nasser S, Reiman R, Phillips L, McDonald J, Adkins J, Mastrian SD, Placek P, Watanabe AT, Lobello J, Han H, Von Hoff D, Craig DW, Stewart AK, Carpten JD.

PLoS Genet. 2014 Feb 13;10(2):e1004135. doi: 10.1371/journal.pgen.1004135. eCollection 2014 Feb.

6.

Fibroblast growth factor receptor 2 fusions as a target for treating cholangiocarcinoma.

Borad MJ, Gores GJ, Roberts LR.

Curr Opin Gastroenterol. 2015 May;31(3):264-8. doi: 10.1097/MOG.0000000000000171. Review.

7.

Biliary papillary tumors share pathological features with intraductal papillary mucinous neoplasm of the pancreas.

Zen Y, Fujii T, Itatsu K, Nakamura K, Minato H, Kasashima S, Kurumaya H, Katayanagi K, Kawashima A, Masuda S, Niwa H, Mitsui T, Asada Y, Miura S, Ohta T, Nakanuma Y.

Hepatology. 2006 Nov;44(5):1333-43.

PMID:
17058219
8.

New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing.

Ross JS, Wang K, Gay L, Al-Rohil R, Rand JV, Jones DM, Lee HJ, Sheehan CE, Otto GA, Palmer G, Yelensky R, Lipson D, Morosini D, Hawryluk M, Catenacci DV, Miller VA, Churi C, Ali S, Stephens PJ.

Oncologist. 2014 Mar;19(3):235-42. doi: 10.1634/theoncologist.2013-0352. Epub 2014 Feb 21.

9.

SOX4 is associated with poor prognosis in cholangiocarcinoma.

Wang W, Zhang J, Zhan X, Lin T, Yang M, Hu J, Han B, Hu S.

Biochem Biophys Res Commun. 2014 Sep 26;452(3):614-21. doi: 10.1016/j.bbrc.2014.08.124. Epub 2014 Aug 30.

PMID:
25181339
10.

Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma.

Arai Y, Totoki Y, Hosoda F, Shirota T, Hama N, Nakamura H, Ojima H, Furuta K, Shimada K, Okusaka T, Kosuge T, Shibata T.

Hepatology. 2014 Apr;59(4):1427-34. doi: 10.1002/hep.26890. Epub 2014 Feb 18.

PMID:
24122810
11.

High throughput molecular profiling reveals differential mutation patterns in intrahepatic cholangiocarcinomas arising in chronic advanced liver diseases.

Jang S, Chun SM, Hong SM, Sung CO, Park H, Kang HJ, Kim KP, Lee YJ, Yu E.

Mod Pathol. 2014 May;27(5):731-9. doi: 10.1038/modpathol.2013.194. Epub 2013 Nov 1.

12.

Fibroblast growth factor receptor 2: a new potential therapeutic target for human cancer.

Cheng C, Hu W, Liu LP, Li J.

Hum Pathol. 2015 Feb;46(2):339-40. doi: 10.1016/j.humpath.2014.10.012. Epub 2014 Nov 3. No abstract available.

PMID:
25466307
13.

Biliary cystic tumors with bile duct communication: a cystic variant of intraductal papillary neoplasm of the bile duct.

Zen Y, Fujii T, Itatsu K, Nakamura K, Konishi F, Masuda S, Mitsui T, Asada Y, Miura S, Miyayama S, Uehara T, Katsuyama T, Ohta T, Minato H, Nakanuma Y.

Mod Pathol. 2006 Sep;19(9):1243-54. Epub 2006 Jun 2.

14.

Clinicopathological characterization of so-called "cholangiocarcinoma with intraductal papillary growth" with respect to "intraductal papillary neoplasm of bile duct (IPNB)".

Nakanuma Y, Sato Y, Ojima H, Kanai Y, Aishima S, Yamamoto M, Ariizumi S, Furukawa T, Hayashi H, Unno M, Ohta T; Hepatolithiasis Subdivision of Intractable Hepatobiliary Diseases Study Group of Japan (Chairman, Hirohito Tsubouchi).

Int J Clin Exp Pathol. 2014 May 15;7(6):3112-22. eCollection 2014.

15.

CD24 expression is a prognostic factor in intrahepatic cholangiocarcinoma.

Su MC, Hsu C, Kao HL, Jeng YM.

Cancer Lett. 2006 Apr 8;235(1):34-9. Epub 2005 Aug 25.

PMID:
16125303
16.

Fascin overexpression is involved in carcinogenesis and prognosis of human intrahepatic cholangiocarcinoma: immunohistochemical and molecular analysis.

Iguchi T, Aishima S, Taketomi A, Nishihara Y, Fujita N, Sanefuji K, Sugimachi K, Yamashita Y, Maehara Y, Tsuneyoshi M.

Hum Pathol. 2009 Feb;40(2):174-80. doi: 10.1016/j.humpath.2008.06.029. Epub 2008 Oct 5.

PMID:
18835624
17.

BRAF V600E-specific immunohistochemistry reveals low mutation rates in biliary tract cancer and restriction to intrahepatic cholangiocarcinoma.

Goeppert B, Frauenschuh L, Renner M, Roessler S, Stenzinger A, Klauschen F, Warth A, Vogel MN, Mehrabi A, Hafezi M, Boehmer K, von Deimling A, Schirmacher P, Weichert W, Capper D.

Mod Pathol. 2014 Jul;27(7):1028-34. doi: 10.1038/modpathol.2013.206. Epub 2013 Dec 6.

18.

Detection of response-predicting mutations in the kinase domain of the epidermal growth factor receptor gene in cholangiocarcinomas.

Gwak GY, Yoon JH, Shin CM, Ahn YJ, Chung JK, Kim YA, Kim TY, Lee HS.

J Cancer Res Clin Oncol. 2005 Oct;131(10):649-52. Epub 2005 Oct 20.

PMID:
16032426
19.

c-erbB-2 protein is expressed in hepatolithiasis and cholangiocarcinoma.

Terada T, Ashida K, Endo K, Horie S, Maeta H, Matsunaga Y, Takashima K, Ohta T, Kitamura Y.

Histopathology. 1998 Oct;33(4):325-31.

PMID:
9822921
20.

The utility of keratin 903 as a new prognostic marker in mass-forming-type intrahepatic cholangiocarcinoma.

Aishima S, Asayama Y, Taguchi K, Sugimachi K, Shirabe K, Shimada M, Sugimachi K, Tsuneyoshi M.

Mod Pathol. 2002 Nov;15(11):1181-90.

Items per page

Supplemental Content

Write to the Help Desk